Adamis Pharmaceuticals (ADMP) PT Lowered to $0.00 at B. Riley
Adamis Pharmaceuticals (NASDAQ:ADMP) had its price target dropped by research analysts at B. Riley in a research report issued to clients and investors on Wednesday. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock.
A number of other equities analysts also recently issued reports on ADMP. Zacks Investment Research downgraded Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 20th. ValuEngine downgraded Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, November 30th. Maxim Group set a $14.00 target price on Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, December 5th. Finally, Raymond James Financial set a $7.00 target price on Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, February 23rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $7.33.
Shares of Adamis Pharmaceuticals (ADMP) traded down $0.25 during mid-day trading on Wednesday, reaching $3.55. The company’s stock had a trading volume of 386,402 shares, compared to its average volume of 829,666. The stock has a market capitalization of $118.52, a P/E ratio of -5.07 and a beta of 0.36. The company has a quick ratio of 3.79, a current ratio of 3.93 and a debt-to-equity ratio of 0.06. Adamis Pharmaceuticals has a 52 week low of $2.35 and a 52 week high of $6.45.
Adamis Pharmaceuticals Company Profile
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.